Clinical Trial Tracker: An Update on Promising Phase 2 and 3 Clinical Trials in Pancreatic Cancer

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: October 24, 2018
Expiration Date: October 24, 2019

Expected time to complete this activity as designed: 15 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Despite recent progress involving adjuvant and neoadjuvant approaches, treatment options for pancreatic ductal adenocarcinoma (PDA) remain unsatisfying, especially in the salvage setting of locally advanced and metastatic disease. Immune therapies have been successful in a number of other tumor types, but pancreatic cancer has been largely refractory to these otherwise exciting approaches. Fortunately, many novel compounds are in development that may well improve long-term outcomes of this challenging malignancy.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including primary care physicians, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Evaluate clinical trials for novel targeted therapy combined with existing chemotherapy regimens in the first-line and second-line setting for metastatic PDA
  • Identify encouraging clinical trials and their potential impact on treatment paradigms upon approval

Agenda

Clinical Trial Tracker: An Update on Promising Phase 2 and 3 Clinical Trials in Pancreatic Cancer – J. Randolph Hecht, MD

Instructions for Participation and Credit

This activity is eligible for credit through October 24, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

J. Randolph Hecht, MD
Professor of Clinical Medicine
David Geffen School of Medicine at UCLA
Director, UCLA Gastrointestinal Oncology Program
Los Angeles, California

Dr. J. Randolph Hecht received his medical degree from Eastern Virginia Medical School. He completed his internal medicine residency at Northwestern, followed by fellowships in gastroenterology research at the University of Chicago and in gastroenterology and medical oncology at UCLA. Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program.

Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has led and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, and leading phase I, II, and III trials with novel immunotherapy agents.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-033-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. J. Randolph Hecht has received honoraria related to formal advisory activities from Rafael Pharmaceuticals, Inc. and as a consultant from F. Hoffmann-La Roche Ltd. and Halozyme, Inc. He has received grant support related to research activities from ARMO Biosciences, Halozyme, and Merrimack Pharmaceuticals, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.